vVardis Holding AG (VVVV), a Swiss dental tech start-up, upsized its IPO at pricing to 9.72 million shares – up from 8.33 million in the prospectus – and priced the deal at $18.00 – $3.00 below range – to raise $174.96 million on Thursday night, Nov. 12, 2026. vVardis Holding’s stock sank in its New […]
November 13, 2026 Read MoreWindward Bio (WWB), a biotech based in Basel, Switzerland, priced its IPO at $17.00 – the mid-point of its range – and sold 10.29 million shares – the number in the prospectus – to raise $174.93 million on Thursday night, Nov. 12, 2026. Windward Bio’s stock jumped in its NASDAQ debut on Friday, Nov. 13, […]
November 12, 2026 Read MoreAnthropic (ANT Proposed), known for its Claude AI platform, launched its $61.05 billion IPO today – Tuesday, Nov. 10, 2026 – after disclosing its terms: 825 million shares at a price range of $70.00 to $78.00 a share to raise $61.05 billion, if priced at the $74.00 mid-point of its range. At pricing, Anthropic would […]
November 10, 2026 Read MoreWindward Bio (WWB Proposed), a Swiss biotech developing long-acting drug candidates to treat asthma, COPD and atopic dermatitis, unveiled the terms early today (Monday, Nov. 9,2026) for its $175 million IPO. Windward Bio is offering 10.29 million shares at a price range of $16.00 to $18.00 to raise $174.93 million, if priced at the $17.00 […]
November 9, 2026 Read MoreTwo healthcare IPOs – Rezera (RZRA Proposed), a biotech targeting peripheral artery disease (PAD), and vVardis Holding AG (VVVV Proposed), a dental products start-up backed by PE player Apollo – are set for pricing this week – the week of Nov. 9, 2026 – to raise a total of $414.3 million. The Street, though, is […]
Read MorevVardis Holding AG (VVVV Proposed), a dental products start-up backed by Apollo, launched its $214.3 million IPO on Friday afternoon – Nov. 6, 2026. The deal is set to price next week. vVardis, based in Zug, Switzerland, is offering 9.52 million shares at a price range of $21.00 to $24.00 to raise $214.29 million, if […]
November 6, 2026 Read MoreRezera Inc. (RZRA Proposed), a Boston biotech planning a Phase 3 trial in 2027 of its leading drug candidate to treat peripheral artery disease (PAD), unveiled the terms for its $200 million IPO early today – Thursday, Nov. 5, 2026 – in an S-1/A filing. Rezera is offering 16.67 million shares at a price range […]
November 5, 2026 Read MoreThe IPO market is in slow-mo mode as November gets under way. No IPOs are scheduled to price this week. That’s not surprising, considering the U.S. stock market’s plunge on Friday,Oct. 30 – marking the Nasdaq’s worst month since March 2025 – and the mid-term U.S. elections tomorrow – on Tuesday, Nov. 3, 2026. The […]
November 2, 2026 Read MoreOPay Ltd. (OPAY), the Nigerian FinTech app, has postponed its IPO indefinitely after the stock did not start trading today, as expected, according to Street sources familiar with the situation, IPOScoop has learned. Clients of a major firm have been notified that it was withdrawing from the IPO. It’s highly unusual for an IPO to […]
October 30, 2026 Read MoreAspen Neuroscience (ASPE), a biotech developing a stem cell therapy to treat patients with Parkinson’s Disease, priced its IPO at $15.00 – the low end of its range – and sold 9.375 million shares – the number in the prospectus – to raise $140.63 million on Thursday night, Oct. 29, 2026. The San Diego-based biotech’s […]
Read More